Literature DB >> 2306746

Response to a standard oral levodopa test in parkinsonian patients with and without motor fluctuations.

M Contin1, R Riva, P Martinelli, G Procaccianti, P Cortelli, P Avoni, A Baruzzi.   

Abstract

The acute dose-response profile of a standard oral levodopa dose was followed, over a maximum 8-h period, in 13 patients with and 10 patients without motor fluctuations using a battery of motor quantitative tests (tapping and walking speed, and multiple choice reaction and movement times). Thirteen age-matched normal controls performed tapping and psychomotor tests, at the same time intervals, over a 4-h period. Tapping test and movement times proved significantly impaired in all patients and were the best indicator of levodopa effect, while walking speed and reaction times were apparently of less value, except in severely affected patients. The duration of the levodopa antiparkinsonian effect differed markedly between the two groups, since fluctuating patients returned to prelevodopa dose values within 4 h (mean +/- SEM: 203 +/- 16 min), while in the stable group motor scores remained significantly higher than baseline values up to at least 7 h postdose. The magnitude of the effect was similar in the two groups, but response was complicated by mild to severe dyskinesias in 9 of 13 fluctuating subjects. The pharmacokinetic parameters of levodopa were almost identical in the two groups. Our data add further weight to the hypothesis that cerebral pharmacokinetic or pharmacodynamic factors are responsible for motor fluctuations. Oral levodopa doses coupled with objective tests of motor performance may prove a practical clinical tool to assess and optimize the relationship between drug dose and therapeutic effect.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2306746     DOI: 10.1097/00002826-199002000-00002

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  15 in total

1.  Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

2.  Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease.

Authors:  M Contin; R Riva; P Martinelli; F Albani; A Baruzzi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.

Authors:  C Colosimo; M Merello; A J Hughes; K Sieradzan; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

4.  Hemiparkinsonism-hemiatrophy: a new observation.

Authors:  P Martinelli; C Scaglione; M Capocasa; F Dalpozzo; M Contin
Journal:  J Neurol       Date:  1998-03       Impact factor: 4.849

5.  High-frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l-3,4-dihydroxyphenylalanine in dopaminergic denervated rats.

Authors:  Emilie Lacombe; Carole Carcenac; Sabrina Boulet; Claude Feuerstein; Anne Bertrand; Annie Poupard; Marc Savasta
Journal:  Eur J Neurosci       Date:  2007-09-06       Impact factor: 3.386

6.  Supervised versus unsupervised technology-based levodopa monitoring in Parkinson's disease: an intrasubject comparison.

Authors:  Giovanna Lopane; Sabato Mellone; Mattia Corzani; Lorenzo Chiari; Pietro Cortelli; Giovanna Calandra-Buonaura; Manuela Contin
Journal:  J Neurol       Date:  2018-03-29       Impact factor: 4.849

Review 7.  Pharmacokinetic optimisation in the treatment of Parkinson's disease.

Authors:  M Contin; R Riva; F Albani; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

8.  Usefulness of movement time in the assessment of Parkinson's disease.

Authors:  M Zappia; R Montesanti; R Colao; A Quattrone
Journal:  J Neurol       Date:  1994-08       Impact factor: 4.849

9.  Quantitative Assessment of Motor Response to a Low Subacute Levodopa Dose in the Differential Diagnosis of Parkinsonisms at Disease Onset: Data from the BoProPark Cohort.

Authors:  Manuela Contin; Giovanna Lopane; Pietro Cortelli; Luisa Sambati; Susan Mohamed; Giovanna Calandra-Buonaura
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

10.  The acute brain response to levodopa heralds dyskinesias in Parkinson disease.

Authors:  Damian M Herz; Brian N Haagensen; Mark S Christensen; Kristoffer H Madsen; James B Rowe; Annemette Løkkegaard; Hartwig R Siebner
Journal:  Ann Neurol       Date:  2014-05-28       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.